TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ovarian epithelial carcinoma not amenable to curative surgery or radiotherapy~  * Evidence of recurrence or progression 6 months after discontinuation of prior first-line platinum-containing regimen~* No tumor of borderline malignancy~* Evaluable disease outside previously irradiated area~* No CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Neutrophil count at least 1,500/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Not specified~Renal:~* Glomerular filtration rate greater than 50 mL/min~Other:~* No concurrent active infection~* No other primary malignancy except carcinoma in situ of the cervix or adequately treated basal cell skin cancer~* No other concurrent serious systemic disorder~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* No more than 1 prior platinum-based chemotherapy regimen~* No prior gemcitabine~* No other concurrent cytotoxic or antineoplastic treatment~Endocrine therapy:~* At least 3 weeks since prior hormonal therapy~* Concurrent hormone replacement therapy allowed~* Concurrent steroid antiemetics allowed~Radiotherapy:~* See Disease Characteristics~* At least 3 weeks since prior radiotherapy (limited to the small pelvis)~* Concurrent palliative radiotherapy to nontarget lesions allowed~Surgery:~* See Disease Characteristics~Other:~* At least 3 weeks since other prior investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Relapsing-remitting MS (Mc Donald criteria 2010) regardless being under immunomodulatory treatment~2. EDSS (previous to relapse) between 0 and 5~3. MS relapse of moderate intensity (EDSS increase from 1 to 2.5 points) or severe intensity (EDSS increase \> 3 points)~   * If EDSS previous relapse is available:~     * optic neuritis, myelitis or brainstem relapse: the EDSS should increase of 1 point in visual, pyramidal or brainstem system function~    * relapse in other location or uncertain location: the EDSS should increase at least 1 point~  * If EDSS previous relapse is not available:~     * optic neuritis, myelitis or brainstem relapse: the visual, pyramidal or brainstem system function should be \> 2 points.~    * relapse in other location or uncertain location: EDSS should be \> 2 points~4. Recent clinical relapse onset (\<15 days) without fever~5. One month of clinical stability prior to relapse~6. Signed informed consent~7. Capacity to ingest the medication.~Exclusion Criteria:~1. Doubts about the diagnosis of multiple sclerosis~2. First episode of inflammatory neurological disease~3. Secondary progressive MS or primary progressive MS~4. Symptoms with lasted less than 24 hours of evolution~5. Any degree of subjective or objective remission~6. Treatment with corticosteroids during the previous 30 days~7. Patients with immunosuppressive treatment (azathioprine, mitoxantrone, cyclophosphamide) or Natalizumab or Fingolimod~8. Pregnancy or breastfeeding women or women of childbearing potential not using contraceptive measures~9. Diseases with a contraindication of treatment with corticosteroids~10. History of serious adverse reaction or hypersensitivity to drugs related to study medication~11. Patients who could not be regular MRI, not collaborators or who requires anesthesia.~12. Lactose intolerance~13. Patients with allergies to contrast used in MRI~14. Patients with renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- oMP 1250 mg: Group A (Type: ACTIVE_COMPARATOR): Methylprednisolone 1250 mg/24h x3 days
- oMP 625 mg: Group B (Type: ACTIVE_COMPARATOR): Methylprednisolone oral 625 mg/24h x3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Polio End-game Strategies - Poliovirus Type 2 Challenge Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Newborn of either gender born healthy with birth weight 2.0 kg or more, with immediate cry, at the study sites (home or health facility births)~* Not planning to travel away during entire the study period (birth-154 days; birth 22 weeks).~* Parents resident of the study area for last 3 month at the time of enrolment~* Parent/guardian provides informed consent~Exclusion Criteria:~* Newborns found acutely ill at the time of enrolment and requiring emergent medical care/hospitalization, birth weight below 2.0 kg, cry \>2 minutes after birth, or family is planning to be absent during the birth - 154 days study period~* Refusal of blood testing and cord blood testing~* Receipt of OPV after birth before eligibility screen~* Newborns with certain medical conditions i.e., syndromic infants, neonate with petechial or purpura (contraindication of intramuscular injections)~* A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family - e.g. several early infant deaths, household member on chemotherapy) will render the newborn ineligible for the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Day
- Healthy Volunteers: f

Study Arms:
- IPV (Type: EXPERIMENTAL): IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks
- bOPV (Type: EXPERIMENTAL): bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age
- bOPV and IPV (Type: EXPERIMENTAL): bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age
- bOPV and IPV and IPV2 (Type: EXPERIMENTAL): bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age
- tOPV (Type: ACTIVE_COMPARATOR): tOPV at birth, 6, 10, 14, 18 and 22 weeks of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aminotransferase Trends During Prolonged Acetaminophen Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 or older~Exclusion Criteria:~1. History of acetaminophen ingestion on any of the four days preceding study enrollment~2. Measurable serum acetaminophen level at time of enrollment~3. Viral markers of Hepatitis B or C, or viral markers of Hepatitis A with an ALT level greater than ULN during screening laboratory testing~4. Serum ALT or AST level greater than ULN at Screening or Day 0~5. Total bilirubin level greater than ULN at Screening or Day 0~6. INR level greater than ULN at Screening~7. Alkaline phosphatase level greater than ULN at Screening~8. Platelet count less than 125 10\^9/L at Screening~9. Known cholelithiasis~10. Positive pregnancy test at Screening (female participants only)~11. History of consuming more than an average of 3 alcohol containing drinks daily over the preceding 2 weeks~12. History of consuming 3 or more alcohol containing drinks on any given day during the 2 weeks prior to study enrollment~13. New prescription medication started within the previous 30 days~14. Currently taking isoniazid~15. Currently taking warfarin~16. Currently adheres to a fasting type diet as determined by self report~17. Currently has anorexia nervosa as determined by self report~18. Participant is clinically intoxicated, psychiatrically impaired or unable to give informed consent for any reason~19. Known hypersensitivity or allergy to acetaminophen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- acetaminophen (Type: EXPERIMENTAL): acetaminophen, 4 grams/day (1 gram every 4 hours for 4 doses)
- placebo (Type: PLACEBO_COMPARATOR): placebo for acetaminophen 4 grams/day (2 caplets every 4 hours for 4 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dose escalation cohorts: subjects with diagnosis of CD22-positive Non-Hodgkin's Lymphoma (NHL) who have had at least 1 prior anticancer treatment, including prior treatment with rituximab and chemotherapy.~* Expanded maximum tolerated dose (MTD) confirmation and preliminary efficacy cohorts: subjects with diagnosis of CD22-positive NHL who have had at least 1 prior anticancer treatment, including prior treatment with rituximab and chemotherapy or newly diagnosed subjects who are not candidates for anthracycline-based therapy.~* At least 1 measurable disease lesion that is \> 1 cm in the longest transverse diameter, with a product of the diameters \> 2.25 cm2 by CT or magnetic resonance imaging (MRI).~Exclusion Criteria:~* Candidate for potentially curative therapy such as stem cell transplantation.~* Prior allogeneic hematopoietic stem cell transplantation (HSCT).~* Prior autologous transplantation, radioimmunotherapy, or other anti CD22 immunotherapy \<= 6 months before the first dose of investigational product.~* More than 3 previous combination chemotherapy (2 or more cytotoxics) anticancer regimens.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (R-CVP) (Type: EXPERIMENTAL): Subjects in arm 1 will be enrolled in dose escalation cohorts that will initially evaluate an escalating dose of cyclophosphamide in combination with set doses of inotuzumab ozogamicin, vincristine, prednisone, and rituximab.
- Arm 2 (R-GDP) (Type: EXPERIMENTAL): Subjects in arm 2 will be enrolled in dose escalation cohorts that will initially evaluate escalating doses of gemcitabine and/or cisplatinum in combination with set doses of inotuzumab ozogamicin, dexamethasone, and rituximab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a proven and documented diagnosis of non-cystic fibrosis idiopathic or post pneumonic bronchiectasis~* Stable pulmonary status and stable regimen of standard treatment at least for the past 30 days~Exclusion Criteria:~* Forced Expiratory Volume 1 \< 35% or \> 80%~* Allergic bronchopulmonary aspergillosis~* Immunodeficiency disease requiring immunoglobulin replacement~* Inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ciprofloxacin Inhale (BAYQ3939) (Type: EXPERIMENTAL): 32.5 mg ciprofloxacin hydrated corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Inhalation of matching placebo twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 but not older than 40 years of age at the time of screening~* Good physical and mental health~* Regular cycles with a usual length between 24 and 35 days~* Body mass index ≥ 18 and ≤ 29~* Willing to give informed consent in writing~Exclusion Criteria:~* Contraindications:~  * known or suspected pregnancy~ * active venous thromboembolic disorder (e.g. deep vein thrombosis,pulmonary embolism)~ * presence or history of severe hepatic disease as long as liver function values have not returned to normal~ * malignancy or pre-malignancy, if sex -steroid-influenced~ * undiagnosed vaginal bleeding~ * hypersensitivity to any of the components of Implanon/Radiopaque Implanon~* Hypertension, i.e. systolic blood pressure \>140 mmHg and/or diastolic blood pressure \> 90 mmHg.~* A history during pregnancy or during previous use of sex steroids of: jaundice and/or severe pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss~* Present use or use during 2 months prior to the start of Implanon/Radiopaque Implanon of one of the following drugs: phenytoin, phenobarbital, primidone, carbamazepine, rifampicin, oxcarbazepine, topiramate, felbamate, ritonavir, nelfinavir, griseofulvin or the herbal remedy St John's wort.~* Administration of investigational drugs within 2 months prior to the start of Implanon/Radiopaque Implanon

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Radiopaque Implanon (ro imp) (Type: ACTIVE_COMPARATOR): The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
- Implanon (imp) (Type: ACTIVE_COMPARATOR): Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genotype 1 hepatitis C infection (confirmed at screening)~* Patient has not received any prior treatment for hepatitis C~* Patient must have had a liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection~* Must agree to use 2 forms of effective contraception throughout study (both males and females)~Exclusion Criteria:~* Infection with HIV or non genotype 1 hepatitis C~* Liver disease not related to hepatitic C infection~* Hepatic decompensation~* Significant laboratory abnormalities or other active diseases~* Pregnant or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMC435 (Type: EXPERIMENTAL): TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Financial Incentives for Smoking Cessation Among Mothers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Expresses interest in quitting smoking~* Express willingness to initiate NRT~* Mother is ≥ 18 years of age~* Self-reported smoking ≥ 10 cigarettes per day for ≥ 1 year, biochemically verified~* Mother has a child \< 12 years of age~* Child resides with mother full-time~* Not currently using any other tobacco cessation medications (e.g. Chantix) or NRT, or willing to stop use prior to participation in the study~* Lives in Chittenden County, Vermont or surrounding counties~* Plans on remaining in the geographical area for the next 12 months~* English-speaking~* Willing to let child participate in the study~Exclusion Criteria:~* Failing to meet any of the above criteria~* Has medical contraindications to NRT products~* Meeting Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for moderate or severe alcohol or drug dependence other than nicotine in the prior 12 months (those on opioid substitution therapy are allowed)~* Current/past psychotic disorder~* Being suicidal~* Currently pregnant or trying to become pregnant in the next 12 months~* Incarceration~* Refusal to participate in study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Best practices (Type: EXPERIMENTAL): Participants will receive the Five As plus a referral to a quit line.
- Best practices and financial incentives (Type: EXPERIMENTAL): Participants will receive the Five As, a referral to a quit line, and financial incentives contingent on biochemically confirmed smoking abstinence
- Best practices, financial incentives, and NRT (Type: EXPERIMENTAL): Participants will receive the Five As, a referral to a quit line, financial incentives contingent on biochemically confirmed smoking abstinence, and nicotine replacement therapy (NRT) provided in the form of both nicotine patches and gum/lozenge for dual therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who understand and sign the consent form for this study.~* Age :20-80, males and females~* Patients at least 6 months after Buerger's disease~* Patients with a luminal stenosis of more than 50% on angiography~* Rutherford class II-4, III-5 or III-6~* Subjects not eligible to undergo a revascularization or vascular bypass graft~* Patients who can't treat with traditional medication and need a arthroplasty.~* Patients whose lesion is 2\~6 cm2 in size~* Duration of pain over Grade 4(11-point numeric scale) : \> 4 months~Exclusion Criteria:~* Subjects who cannot survive more than 6 months with critical other complications.~* Patient with well-known active malignant tumor.~* Patients who exceed normal reference values from following test : PAP smear screening, chest X-ray, PSA, mammogram, occult blood test~* Patients in need of a immediate amputation and have a potentially life-threatening complications of critical ischemia~* Patients with uncontrolled iliac artery obstruction of targeted areas.~* Condition with targeted lower limb that have widespread necrosis or in need of amputation.~* End-stage renal failure patients who depend on hemodialysis~* Patients with uncontrolled diabetes mellitus (HbA1c \> 10%).~* Treatment with immunosuppressant (prednisone \> 5mg/day).~* Treatment with a anti-inflammatory drugs within 1 weeks prior to enrollment.~* Women who are pregnant or breast feeding or planning to become pregnant during the study.~* Subjects who have cerebrovascular accident within 6 months prior to inclusion in the study.~* Patients with acute myocardial infarction, angina pectoris.~* Subjects who had been underwent a cardiovascular surgery such as carotid endarterectomy, arterial aneurysm, bypass surgery and coronary bypass surgery within 3 months prior to inclusion in the study.~* Participation in another clinical trial or treatment with a different investigational product within 3 months prior to inclusion in the study.~* Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RNL-Vascostem® (Type: EXPERIMENTAL): drug name and ingredients : RNL-Vascostem\[Autologous adipose tissue derived mesenchymal stem cells\] dosage : Intramuscular infusion, 5 x 10e6 cells/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Melatonin on Insomnia Symptoms in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of insomnia~* Low melatonin levels at study entry~Exclusion Criteria:~* History of sleep apnea (temporary cessation of breathing during sleep)~* Diagnosis of restless legs syndrome~* Current alcohol or substance abuse~* Dementia~* Anemia~* Liver disease~* Leukemia or lymphoma~* Asthma

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Melatonin 0.4 mg
- B (Type: EXPERIMENTAL): Melatonin 4.0 mg
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete